Proteomics International Laboratories Ltd (ASX:PIQ) has been granted a patent for PromarkerD, a diagnostic and predictive test for diabetic kidney disease, in Indonesia.
Concurrently, Proteomics International has secured TGA regulatory approval for the PromarkerD software as an in vitro diagnostic (IVD) for export use.
The regulatory approval covers use of the PromarkerD software algorithm across Proteomics International's different platform technologies, which include both mass spectrometry and immunoassay formats.
The successful TGA approval for PromarkerD software as an IVD forms part of Proteomics International's ongoing strategy to gain regulatory approvals for the pioneering test in multiple jurisdictions.
Proteomics's PromarkerD software hub enables the delivery of results of the proprietary PromarkerD algorithm to Proteomics International's partners around the world.
The remote software hub provides an additional level of intellectual property security to complement patent protection of the PromarkerD biomarkers.
The Indonesian patent number W00 2013 01585 titled “Biomarkers Associated with Diabetic Nephropathy” will extend until September 20, 2031.
Indonesia has 10.3 million adults with diabetes, which ranks the nation sixth in the International Diabetes Federation estimates for diabetes burden.
Given Proteomics’ ambitions to execute licensing transactions globally, the granting of the Indonesian patent secures another potentially lucrative jurisdiction.